Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network.
Times cited: 2028
Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
Journal of Clinical Oncology.
Times cited: 340